<DOC>
	<DOCNO>NCT01715493</DOCNO>
	<brief_summary>The aim study assess effectiveness small airway inflammation 4 week lysozyme administration Chronic Obstructive Pulmonary Disease ( COPD ) and/or asthma .</brief_summary>
	<brief_title>Pharmacological Effect Lysozyme Chronic Obstructive Pulmonary Disease Asthma With Sputum Symptom</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Muramidase</mesh_term>
	<criteria>Inclusion criterion : For COPD : Over 20 year age 85 year age Smoking history Brinkman index 200 Diagnosis COPD Forced expiratory volume 1 second ( FEV1 ) &lt; 80 % predict value Ratio FEV1 force vital capacity ( FVC ) &lt; 70 % symptom expectorate sputum For Asthma Over 20 year age 85 year age Scored 20 24 ACT ( Asthma Control Test ) Symptom expectorate sputum Diagnosed partly control global initiative asthma Exclusion criterion : Egg allergy Domiciliary oxygen therapy Pneumonia pulmonary tuberculosis Patients severe cardiovascular disorder , severe kidney disorder , severe hepatic disorder , severe hematological disorder Cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Asthma</keyword>
	<keyword>Lysozyme Hydrochloride</keyword>
</DOC>